Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Jessica Leng, Jack Khouri, Allison M. Winter, Deepa Jagadeesh, Robert M. Dean, Taylor R. Brooks, Louis Williams, Faiz Anwer, Craig S. Sauter, Brian T. Hill, Paolo F. Caimi

Blood (2024) 144 (Supplement 1): 6342.

https://doi.org/10.1182/blood-2024-206344

Published: 2024

Journal Articles

Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®

Allison M. Winter, Olivia Landever, Hiruni Mendries, Willem Van Heeckeren, Chieh-Lin Fu, Robert M. Dean, Taylor R. Brooks, Deepa Jagadeesh, Paolo F. Caimi, Brian T. Hill

Blood (2024) 144 (Supplement 1): 3247.

https://doi.org/10.1182/blood-2024-200306

Published: 2024

Journal Articles

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Paolo F. Caimi, Allison M. Winter, Robert M. Dean, Taylor R. Brooks, Deepa Jagadeesh, Craig S. Sauter, Brian T. Hill

Blood (2024) 144 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2024-202154

Published: 2024

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Deepa Jagadeesh, Paolo Caimi, Allison Winter, Wei Wei, Brad Pohlman, Christopher D'Andrea, Emily Rhoades, Robert M. Dean, Brian T. Hill

Blood (2023) 142 (Supplement 1): 6233.

https://doi.org/10.1182/blood-2023-191345

Published: 2023

Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2023-173943

Published: 2023

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy

Merve Kacar, Robert M. Dean, Allison Winter, Brad Pohlman, Deepa Jagadeesh, Brian T. Hill, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 6198.

https://doi.org/10.1182/blood-2023-190885

Published: 2023

Journal Articles

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 10596–10597.

https://doi.org/10.1182/blood-2022-168810

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Journal Articles

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Seema Patel, Danielle Cenin, Donna Corrigan, Betty K. Hamilton, Matt Kalaycio, Ronald M. Sobecks, Faiz Anwer, Jack Khouri, Robert M. Dean, Allison Winter, Deepa Jagadeesh, Brad Pohlman, Brian T. Hill, Craig S. Sauter, Paolo F. Caimi

Blood (2022) 140 (Supplement 1): 5073–5074.

https://doi.org/10.1182/blood-2022-169809

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

Journal Articles

Cell Product Differences on Incidence of Venous Thromboembolism in Patients Treated with CAR T-Cells for Aggressive B-Cell Lymphomas

Taylor Brooks, Agrima Mian, Betty K. Hamilton, Robert M. Dean, Allison Winter, Deepa Jagadeesh, Craig S. Sauter, Brian T. Hill, Paolo F Caimi

Blood (2022) 140 (Supplement 1): 12773–12774.

https://doi.org/10.1182/blood-2022-170350

Published: 2022

Journal Articles

Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Rajshekhar Chakraborty, Tapas Ranjan Behera, Hong Li, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Allison Winter, Faiz Anwer, Brad Pohlman, Ronald M. Sobecks, Betty K. Hamilton, Navneet S. Majhail

Blood (2022) 140 (Supplement 1): 10926–10927.

https://doi.org/10.1182/blood-2022-166904

Published: 2022

Journal Articles

Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers

Haikoo Shah, Danielle O'Conke, Ran Zhao, Akansha Jalota, Manishkumar S. Patel, Allison Winter, Louis S. Williams, Jack Khouri, Deepa Jagadeesh, Faiz Anwer, Robert M. Dean, Betty K. Hamilton, Ronald M. Sobecks, Brad Pohlman, Paolo F. Caimi, Craig S. Sauter, Neetu Gupta, Brian T. Hill

Blood (2022) 140 (Supplement 1): 4673–4675.

https://doi.org/10.1182/blood-2022-169412

Published: 2022

Journal Articles

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Lisa A. Rybicki, Taylor Lucas, Donna Corrigan, Matt Kalaycio, Rabi Hanna, Seth J Rotz, Robert M. Dean, Aaron T. Gerds, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Edward A. Copelan, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 99.

https://doi.org/10.1182/blood-2021-149686

Published: 2021

NARROW

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Cell Product Differences on Incidence of Venous Thromboembolism in Patients Treated with CAR T-Cells for Aggressive B-Cell Lymphomas

Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only